Oncology

But researchers have not explained possible causative mechanism

Treatment with exemestane and everolimus may signal new approach

In separate study, MarginProbe device improves results of tumour excision

Resection of primary tumour was associated with improved survival in one study, but did not benefit patients in another

Women may be able to add more than six months to progression-free survival in metastatic breast cancer with drugs that target the family of HER2 genes, according to data out of the CLEOPATRA (CLinical Evaluation Of Pertuzumab And TRAstuzumab) trial.

But researcher notes it’s too early to recommend screening

A study said to be the largest to investigate the tolerability of tamoxifen in male breast cancer patients has shown that many men stop taking the drug early because of side-effects.

CANO/ACIO recommends all patients receive cancer chemotherapy from RNs with additional education and who demonstrate ongoing competency.